Sera Prognostics (NASDAQ:SERA) is a molecular diagnostics company headquartered in Salt Lake City, Utah, focused on transforming prenatal care through advanced predictive testing. Founded in 2014 as a spin-out from Stanford University research, the company leverages proprietary proteomic and bioinformatic technologies to identify biomarkers associated with preterm birth. Under the leadership of CEO Glynis A. Darnell and a management team with extensive experience in biotechnology and women’s health, Sera Prognostics aims to improve clinical outcomes for expectant mothers and infants.
The company’s flagship offering is the PreTRM® test, a blood-based assay designed to assess a pregnant individual’s risk of spontaneous preterm birth between 19 and 20 weeks of gestation. By measuring the ratio of two key proteins in maternal serum, PreTRM® provides clinicians with an early risk stratification tool, enabling timely intervention strategies such as specialized monitoring, lifestyle counseling or prophylactic therapies. Sera Prognostics continues to expand its pipeline of pregnancy-related diagnostics, exploring additional biomarkers for conditions like preeclampsia and other adverse maternal-fetal outcomes.
To date, Sera Prognostics has established collaborations with leading academic institutions, contract research organizations and healthcare providers across the United States. The company participates in clinical trials and validation studies to support regulatory submissions and broaden adoption in obstetric practice. While operations remain focused on North America, Sera Prognostics is exploring partnerships to extend access to its diagnostics in Europe, Asia and other global markets where preterm birth poses a significant public health challenge.
Since its inception, Sera Prognostics has secured funding through private placements and initial public offerings, positioning the company for continued growth in women’s health diagnostics. Its scientific advisory board comprises experts in maternal-fetal medicine, proteomics and obstetric epidemiology, ensuring that the company’s research and development efforts remain at the forefront of prenatal risk assessment. As the burden of preterm birth continues to rise globally, Sera Prognostics is poised to deliver innovative tools that empower clinicians and expectant families with actionable insights early in pregnancy.
